source
- Sanofi's Infilbray receives first U.S. approval for treating neurological symptoms of Gaucher diseaseSanofi announced that the U.S. Food and Drug Administration has granted approval for Infilbray, a therapy aimed at the neurological manifestations of Gaucher disease, a rare genetic disorder. The…
- Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchaseMerck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…